Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
- Author:
Stephen L CHAN
1
;
Sin T CHAN
;
Eric H CHAN
;
Zhe-Xi HE
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; drug therapy; Albumins; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Camptothecin; analogs & derivatives; Deoxycytidine; analogs & derivatives; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; drug therapy; Quinazolines; Receptor, Epidermal Growth Factor; Receptors, Vascular Endothelial Growth Factor
- From:Chinese Journal of Cancer 2014;33(6):267-276
- CountryChina
- Language:English
- Abstract: There have been many clinical trials conducted to evaluate novel systemic regimens for unresectable pancreatic cancer. However, most of the trial results were negative, and gemcitabine monotherapy has remained the standard systemic treatment for years. A number of molecular targeted agents, including those against epidermal growth factor receptor and vascular endothelial growth factor receptors, have also been tested. In recent years, there have been some breakthroughs in the deadlock: three regimens, namely gemcitabine-erlotinib, FOLFIRINOX, and gemcitabine-nab-paclitaxel, have been shown to prolong the overall survival of patients when compared with gemcitabine monotherapy. In addition, emerging data suggested that the membrane protein human equilibrative nucleotide transporter 1 is a potential biomarker with which to predict the efficacy of gemcitabine. Here we review the literature on the development of systemic agents for pancreatic cancer, discuss the current choices of treatment, and provide future directions on the development of novel agents.
